Holen Sie sich die Stockscreener-App
3.01
1.31%
-0.04
Schlusskurs vom Vortag:
$3.05
Offen:
$3.06
24-Stunden-Volumen:
251.56K
Relative Volume:
0.90
Marktkapitalisierung:
$306.34M
Einnahmen:
$4.28M
Nettoeinkommen (Verlust:
$-84.59M
KGV:
-3.585
EPS:
-0.8396
Netto-Cashflow:
$-87.79M
1W Leistung:
-0.66%
1M Leistung:
+9.06%
6M Leistung:
-12.24%
1J Leistung:
+76.02%
1-Tages-Spanne:
$3.00
$3.16
1-Wochen-Bereich:
$2.90
$3.16
52-Wochen-Spanne:
$1.51
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
3.01 | 306.34M | 4.28M | -84.59M | -87.79M | -0.8396 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-31 | Eingeleitet | BTIG Research | Buy |
| 2019-02-01 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-04 | Eingeleitet | UBS | Buy |
| 2018-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-10-18 | Eingeleitet | Jefferies | Buy |
| 2016-10-18 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
MSN Money - MSN
AC Immune Releases Q1 2026 Financial Results - AlphaStreet
ACIU Reports Strong Q1 Revenue Growth and Advances Neurodegenera - GuruFocus
AC Immune reports Q1 EPS (15c), consensus (14c) - TipRanks
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline - TipRanks
AC Immune doses first patient in final ABATE trial cohort By Investing.com - Investing.com South Africa
AC Immune doses first patient in final ABATE trial cohort - Investing.com
AC Immune First Quarter 2026 Financial and Corporate Updates - The Manila Times
AC Immune: Q1 Earnings Snapshot - Barchart.com
AC Immune (NASDAQ: ACIU) trims Q1 2026 loss, sees cash runway into Q4 2027 - Stock Titan
AC Immune (NASDAQ: ACIU) triggers $12M Takeda milestone with final ABATE cohort - Stock Titan
AC Immune lines up 3 brain-disease trial readouts for 2026 - Stock Titan
$12M milestone as AC Immune adds final Alzheimer's trial cohort - Stock Titan
AC Immune SA (HAM:IMR) Dividend - GuruFocus
AC Immune SA (HAM:IMR) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling AC Immune SA (HAM:IMR) Stock Today? - GuruFocus
AC Immune SA Stock Baskets - GuruFocus
AC Immune Stock Operating Data - GuruFocus
AC Immune SA (HAM:IMR) Stock Earnings Transcripts - GuruFocus
AC Immune SA (HAM:IMR) Stock Price, Trades & News - GuruFocus
AC Immune SA (HAM:IMR) Stock News, Headlines & Updates - GuruFocus
AC Immune SA (HAM:IMR) Stock HoldersInstitutional & Insider Ownership - GuruFocus
AC Immune SA (HAM:IMR) Competitors 2026 - GuruFocus
AC Immune SA (HAM:IMR)Valuation Measures & Financial Statistics - GuruFocus
ACIU stock rallies 16.3% in a week: Here's what you need to know - MSN
ACIU.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ACIU.O Technical Analysis & Stock Price Forecast - Intellectia AI
AC Immune revises collaboration with Eli Lilly on tau-targeting Alzheimer’s therapy - MSN
ACIU Should I Buy - Intellectia AI
ACIU.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ACIU.O PE Ratio & Valuation, Is ACIU.O Overvalued - Intellectia AI
ACIU.O Forecast — Price Prediction for 2026. Should I Buy ACIU.O? - Intellectia AI
Martin Zuegel Net Worth (2026) - GuruFocus
Renee Aguiar Lucander Net Worth (2026) - GuruFocus
Carl Howard June Net Worth (2026) - GuruFocus
Monika Buetler Net Worth (2026) - GuruFocus
Top Executive Makes Notable Move With Fresh AC Immune Stock Sale - TipRanks
Roy Ervin Twyman Net Worth (2026) - GuruFocus
Christopher James Roberts Net Worth (2026) - GuruFocus
Piergiorgio Donati Net Worth (2026) - GuruFocus
Insider Stock Purchases: April 16, 2026 - Moomoo
AC Immune (ACIU) CEO Pfeifer logs 10,000-share sale in amended Form 4 - Stock Titan
AC Immune (ACIU) CEO adds 10,000 shares in open-market buy - Stock Titan
Andrea Pfeifer (NASDAQ: ACIU) plans sale of 10,000 shares under Form 144 - Stock Titan
AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy - Greater Geneva Bern area
Leerink Says AC Immune (ACIU) Eli Lilly Tau Program Amendment Is Great News - Insider Monkey
Finanzdaten der Ac Immune Sa-Aktie (ACIU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):